Amgen submits MAA in Europe for Humira biosimilar ABP 501

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen (NASDAQ:AMGN) submits its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 501, its biosimilar to AbbVie's (NYSE:ABBV) Humira (adalimumab) which is cleared in a range of countries around the world for the treatment of various inflammatory diseases.

The company submitted in Biologics License Application (BLA) to the FDA on November 25.

Previously: Amgen submits first BLA for Humira biosimilar (Nov. 25)

Subscribe for full text news in your inbox